Spark Therapeutics pharma alliances with big pharma giant Pfizer to develop and commercialize SPK-FIX, a potential treatment for hemophilia B.
Under the terms of the deal, Pfizer will pay Spark an upfront fee of $20 million.
Additional milestone payments to Spark could total $260 million for the development of multiple hemophilia B products.
Spark will fund the Phase 1/2 studies of SPK-FIX, while Pfizer will pay for pivotal studies, regulatory approvals and global commercialization of the products.
In addition, Spark is entitled to receive double-digit royalties based on global product sales.
A rare inherited hematologic disorder, hemophilia B, is characterized by a mutation in the Factor IX, or FIX, gene, which leads to deficient blood coagulation and an increased risk of hemorrhaging.
Pfizer also emphasized the synergy between the two companies.
For further deal information visit Current Agreements (subscription required)
Report: Top 50 Big Biotech Partnering and M&A Deal Trends